Format

Send to

Choose Destination
See comment in PubMed Commons below
Rev Neurol (Paris). 2013 Feb;169 Suppl 1:S33-8. doi: 10.1016/S0035-3787(13)70058-4.

Treatment of chronic immune-mediated neuropathies: impact of the rare diseases centers network in Italy.

Author information

  • 1Department of Medical Biotechnology and Translational Medicine (BIOMETRA), University of Milan, 2nd Neurology, IRCCS Humanitas Clinical Institute, Via Manzoni 56, 20089, Rozzano, Milan, Italy. eduardo.nobile@unimi.it

Abstract

Chronic immune-mediated neuropathies represent a heterogeneous group of mostly demyelinating neuropathies thought to be caused by an autoimmune response to peripheral nerve antigens. They include chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and related variants, multifocal motor neuropathy (MMN) and neuropathy associated with an IgM monoclonal gammopathy with antibody activity against myelin-associated glycoprotein (MAG). Most of these neuropathies respond to immune therapy even though their response to therapy may be different, thereby confirming that their distinct characteristics have relevant clinical implications. While clinicians and scientists are intrigued by the desire to better clarify the cause and pathogenesis of these disorders, the need to allow affected patients to be reimbursed by insurance companies or the national health system can lead to the risk of lumping all these neuropathies under the umbrella term of 'CIDP' to facilitate patients' access to costly therapies.

Copyright © 2013 Elsevier Masson SAS. All rights reserved.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Masson (France)
    Loading ...
    Write to the Help Desk